Zai Lab (ZLAB) Cash & Equivalents (2016 - 2026)
Zai Lab (ZLAB) posted Cash & Equivalents of $651.3 million for Q1 2026, down 4.16% sequentially from $679.6 million in Q4 2025, and down 13.99% YoY from $757.3 million in Q1 2025.
Analysis
Zai Lab (ZLAB) Cash & Equivalents (2016 - 2026) Analysis & Trends
Zai Lab has reported Cash & Equivalents for 11 years, with the latest figure at $651.3 million in Q1 2026.
- Quarterly Cash & Equivalents fell 13.99% year-over-year to $651.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $651.3 million (down 13.99% YoY) and the FY2025 annual result came in at $679.6 million, up 51.13% from the prior year.
- Cash & Equivalents eased to $651.3 million in Q1 2026 per ZLAB's latest filing, from $679.6 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $1.1 billion in Q3 2022 and troughed at $449.7 million in Q4 2024.
- A 5-year average of $756.3 million and a median of $732.2 million in 2025 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2022 and 2025: Cash & Equivalents slumped 61.46% in 2022, then surged 51.13% in 2025.
- Over 5 years, Cash & Equivalents stood at $1.0 billion in 2022, then dropped by 21.65% to $790.2 million in 2023, then slumped by 43.09% to $449.7 million in 2024, then soared by 51.13% to $679.6 million in 2025, then decreased by 4.16% to $651.3 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $651.3 million, $679.6 million, and $717.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 1.72 Bn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 815.44 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 1.71 Bn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 811.99 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Zai Lab | 2.94 Bn | 2.23 Bn | 58.15 Mn | 607.52 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 607.52 Mn |
| Mar 31, 2026 | 651.32 Mn |
| Dec 31, 2025 | 679.57 Mn |
| Sep 30, 2025 | 717.16 Mn |
| Jun 30, 2025 | 732.16 Mn |
| Mar 31, 2025 | 757.26 Mn |
| Dec 31, 2024 | 449.67 Mn |
| Sep 30, 2024 | 616.09 Mn |
| Jun 30, 2024 | 630.05 Mn |
| Mar 31, 2024 | 650.78 Mn |
| Dec 31, 2023 | 790.15 Mn |
| Sep 30, 2023 | 788.81 Mn |
| Jun 30, 2023 | 859.16 Mn |
| Mar 31, 2023 | 879.84 Mn |
| Dec 31, 2022 | 1.01 Bn |
| Sep 30, 2022 | 1.12 Bn |
| Jun 30, 2022 | 680.82 Mn |
| Mar 31, 2022 | 846.96 Mn |
| Dec 31, 2021 | 964.10 Mn |
| Sep 30, 2021 | 1.40 Bn |